SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the study drug SOM 230 in addition to
standard therapy of gemcitabine can shrink or slow the growth of pancreatic cancer. The
safety and tolerability of different doses of SOM 230 will also be studied. The participants'
physical state, changes in the size of the tumor, and laboratory findings taken while
on-study will help us (the study doctor and Moffitt Cancer Center) decide if SOM 230 is safe
and effective.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute